$-0.01 EPS Expected for ICC International Cannabis Corp (ICC)

November 15, 2017 - By Hazel Jackson

 $ 0.01 EPS Expected for ICC International Cannabis Corp (ICC)

Investors wait ICC International Cannabis Corp (CVE:ICC) to report on December, 5. its quarterly earnings ICC International Cannabis Corp’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.01 EPS reproted in the previous quarter, It closed at $1.03 lastly. It is up 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

ICC International Cannabis Corp, formerly Shogun Capital Corp, is a Canada company, which is a licensed cannabis producer, investigator and vendor. The company has market cap of $115.94 million. The principal activities of the Company are the production and sale of cannabis from its facilities in Uruguay. It currently has negative earnings. The Firm is focused on the licensed production, development and sale of recreational cannabis, cannabinoid extracts and by-products for medicinal uses and industrial hemp.

More notable recent ICC International Cannabis Corp (CVE:ICC) news were published by: Marketwatch.com which released: “ICC International Cannabis Corporation Commences CBD Flower Production for …” on May 31, 2017, also Marketwatch.com with their article: “ICC International Cannabis Corporation Provides Update on Recreational …” published on August 09, 2017, Globenewswire.com published: “ICC International Cannabis Corporation Provides Cannabinoid Extract Business …” on October 04, 2017. More interesting news about ICC International Cannabis Corp (CVE:ICC) were released by: Marketwired.com and their article: “ICC International Cannabis Corporation Files Final Short Form Prospectus” published on November 14, 2017 as well as Marketwatch.com‘s news article titled: “ICC International Cannabis Corporation Announces Regulatory Approval of …” with publication date: July 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.